Brand product · Semaglutide
Wegovy: FDA Status, Uses, Safety and Cost
Single receptor target (GLP-1)
What Wegovy is
Wegovy is Novo Nordisk’s brand of semaglutide approved specifically for chronic weight management — the first GLP-1 medication approved for weight management in adults since 2014. It is also approved to reduce cardiovascular risk in adults with heart disease and obesity or overweight. It contains the same active ingredient as Ozempic but at different doses and with different approved uses.
Key facts
| Generic (active ingredient) | Semaglutide |
|---|---|
| Brand names | Wegovy |
| Drug class | GLP-1 receptor agonist |
| Manufacturer | Novo Nordisk |
| FDA status | FDA ApprovedApproved for chronic weight management |
| Administration | Subcutaneous injection (prefilled pen) |
| Frequency | Once weekly |
| Approval date | June 2021 (adults); December 2022 (adolescents 12+); March 2024 (cardiovascular risk reduction) |
| Prescription required | Yes |
| Official label | Prescribing information (DailyMed) |
What Wegovy is approved for
- Chronic weight management in adults with obesity (BMI ≥30), or overweight (BMI ≥27) with at least one weight-related condition, as an adjunct to a reduced-calorie diet and increased physical activity
- Chronic weight management in pediatric patients aged 12 and older with obesity
- Reduction of risk of major adverse cardiovascular events (cardiovascular death, heart attack, stroke) in adults with established cardiovascular disease and either obesity or overweight
How Wegovy works
Wegovy’s active ingredient, semaglutide, mimics the GLP-1 hormone: it acts on brain regions involved in appetite, increases fullness, and slows stomach emptying, reducing calorie intake.
- 1
Medication binds
A GLP-1 receptor agonist activates the receptor for the natural GLP-1 hormone.
- 2
Signals are sent
Appetite-regulating areas of the brain are affected, increasing fullness.
- 3
Stomach slows
Gastric emptying slows, so food stays in the stomach longer.
- 4
Intake falls
Per FDA labeling, weight reduction happens mainly through eating fewer calories.
Administration
Wegovy is given by subcutaneous injection (prefilled pen), once weekly.
We do not publish dosing guidance
Dose selection, titration schedules, and what to do about a missed dose are individual clinical decisions. Follow the instructions from your prescriber and the official prescribing information — never a website.
Important safety information
Boxed Warning — the FDA’s most serious warning
Risk of thyroid C-cell tumors: caused thyroid C-cell tumors in rodents at clinically relevant exposures; it is unknown whether this occurs in humans. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Summarized from the product’s FDA prescribing information. Read the full label, linked in Sources below.
Contraindications (who should not take it)
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known serious hypersensitivity to semaglutide or product components
Summarized from the FDA prescribing information. This is not the complete list — see the full label.
Common adverse reactions from official labeling
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Headache
- Fatigue
- Dyspepsia (indigestion)
- Dizziness
- Abdominal distension
The most common adverse reactions listed in the product’s FDA prescribing information. Frequency and full adverse-reaction data are in the label.
Brand and generic relationships
Wegovy is a brand product containing the active ingredient semaglutide.
Cost and access
- Prescription only, from a licensed clinician; dispensed by licensed pharmacies.
- Novo Nordisk’s NovoCare platform offers a savings program for eligible commercially insured patients and self-pay options; eligibility rules and amounts change — verify current terms on the official site.
- The FDA has warned about counterfeit Wegovy/semaglutide sold by unlicensed online sellers — only use state-licensed pharmacies.
Why we don't publish a price
List prices, savings-card amounts, and self-pay offers change frequently and vary by pharmacy, plan, and location. Any figure we printed would be wrong for many readers and stale within weeks. See our cost guide for how to get an accurate number for your own situation.
Insurance considerations
- Commercial coverage for the weight-management indication varies by employer plan; prior authorization is common.
- Medicare Part D cannot cover Wegovy for weight loss (statutory exclusion), but per 2024 CMS guidance may cover it for the cardiovascular risk-reduction indication in beneficiaries who qualify.
- Medicaid coverage varies by state.
More detail: how insurance coverage works for weight-loss medication.
Comparisons
Frequently asked questions
- Is Wegovy the same as Ozempic?
- They contain the same active ingredient (semaglutide) from the same manufacturer, but Wegovy is approved for chronic weight management and cardiovascular risk reduction while Ozempic is approved for type 2 diabetes, and their dose strengths differ. See our Ozempic vs. Wegovy comparison.
- Does insurance cover Wegovy?
- It depends on your plan. Many employer plans exclude weight-management drugs; others cover Wegovy with prior authorization. Medicare may cover it only for the cardiovascular indication. Check your plan’s formulary — our insurance guide explains how.
- Is there a generic Wegovy?
- No. There is no FDA-approved generic semaglutide. Compounded semaglutide is not a generic and is not FDA approved.
Related guides
Sources
- Wegovy prescribing information (DailyMed, NIH) — DailyMed/NIH. Link last verified August 12, 2026.
- FDA: Medications containing semaglutide — FDA. Link last verified August 12, 2026.
- Wegovy official site (Novo Nordisk) — Manufacturer. Link last verified August 12, 2026.
Not medical advice. WeightLossDrugsGuide is an independent educational publisher. We are not a pharmacy, a medical provider, or a telehealth clinic, and we do not provide personalized medical recommendations or dosing guidance. Information here summarizes official FDA labeling and other primary sources and may not reflect the most recent changes. Always talk with a licensed clinician about your own situation, and read the full prescribing information for any medication.